Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Most Dormant HIV Particles Found To Be Highly Mutated And Harmless

XTALKS VITALS NEWS

HIV

In their analysis, the researchers found that over 90 percent of the sequenced provirus contained a number of mutations which would render them nonfunctional.

Tweetables from this article:

Tweet: Methods currently in use to measure levels of dormant #HIV in patients, may be fatally flawed http://ctt.ec/bU085+Methods currently in use to measure levels of dormant HIV in patients, may be fatally flawed.

Tweet: Johns Hopkins researchers find over 90% of the sequenced provirus contained mutations which render them nonfunctional http://ctt.ec/UYod6+Johns Hopkins researchers find over 90% of the sequenced provirus contained mutations which render them nonfunctional.

Share this!

August 10, 2016 | by Sarah Massey, M.Sc.

Researchers at Johns Hopkins Medicine say that the methods currently in use to measure levels of dormant HIV in patients, may be fatally flawed. According to the study investigators, many of the latent HIV proviruses – or those whose genetic information has been incorporated into the DNA of the infected host – are heavily mutated and are unlikely to be harmful.

Currently, HIV proviruses are quantified using polymerase chain reaction (PCR) to amplify certain HIV-specific genes. If most HIV genes are defective to the point of nonfunctioning, as the researchers have found, then this technique may be over estimating the number of latent viruses, which have the potential to reactivate and sicken the patient.

In order to come to their conclusions, the Johns Hopkins researchers sequenced the provirus genomes from 19 patients who were receiving treatment for HIV. In their analysis, they found that over 90 percent of the sequenced provirus contained a number of mutations which would render them nonfunctional.

Interestingly, the prevalence of defective proviruses was even identified in patients in very early stages of HIV infection, and those who were starting treatment right away. According to the researchers, their work – which was published in the journal, Nature Medicine – suggests that we must develop a new method to quantify the number of non-defective proviruses, as this is the number that could give patients and physicians an idea of how well certain HIV therapies are working.

“To cure HIV, you want to get rid of the proviruses without defects,” said Dr. Robert Siliciano, an infectious disease physician and molecular biologist at the Johns Hopkins University School of Medicine, and the senior author on the publication. “But our work shows that the standard assays used to do that are measuring forms of the virus that are not really relevant to these cure strategies.”

Antiretroviral therapies, which inhibit the virus from using the cell’s machinery to replicate, are the current standard of care for treating HIV infection. However, these drugs are unable to target the latent form of the virus, which lay dormant in certain types of cells within the immune system.



These proviruses can eventually reactivate, causing a recurrent infection in patients who may no longer be taking antiretroviral drugs. Siliciano, says that attempts to target these latent provirus reservoirs have so far proved unsuccessful.

Oftentimes when testing an experimental new HIV therapy, researchers measure levels of provirus reservoirs both before and after treatment, to gauge its effectiveness. Using PCR, the resulting provirus estimates include both virulent and defective HIV genes – a fact that wasn’t always considered to be a problem by researchers.

“Most of us in the field assumed that the initial pool of latent proviruses, immediately after infection, contained entirely functional copies of the virus, so we also assumed that PCR—at least for patients treated with antiretroviral therapy early in the course of infection—would mostly be counting proviruses that had the ability to cause disease again,” said Katherine Bruner, a graduate student in Siliciano's laboratory, and the primary author on the paper. But Siliciano and colleagues’ results painted a different picture. “Even in patients treated really early, if you're using a PCR-based approach to measure the reservoir, you're really just detecting a lot of defective proviruses,” continued Bruner.

The researchers are hopeful that their results will help others better understand what the PCR technique is actually measuring. By knowing that those defective proviruses are found in large numbers early in the HIV infection, researchers will be able to account for this in their evaluation of new therapies.


Keywords: HIV, Therapy, PCR


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
Lavazza Acquires Controlling Stake in Canada’s Kicking Horse Coffee

May 26, 2017 - Italian coffee company Lavazza, has secured an 80 percent equity stake in Canadian organic and fair-trade coffee company Kicking Horse Coffee, in a deal worth CAD$215 million.

Featured In: Food News


FDA First: Keytruda Approved for Cancer Treatment Based on Biomarker Alone

May 25, 2017 - For the first time, the FDA has approved a cancer treatment for solid tumors based on the presence of a biomarker, as opposed to specifying a tissue of origin.

Featured In: Biotech News


One Year of Medically Assisted Dying in Canada

May 25, 2017 - In June of 2016, the federal government of Canada passed legislation to legalize medically assisted dying.

Featured In: Life Science News


LEAVE A COMMENT
 
  
THE XTALKS VITALS INDUSTRY BLOG

Top 5 Most Impactful Tweets in Life Sciences During the Last Week

REGISTER FOR THESE WEBINARS

EU IVD Regulation: Top Five Changes for Medical Device Manufacturers to Consider


Thermal Processing Systems for the Food Industry: A Guide to Selecting Thermal Equipment and Technology


Rare Disease & Orphan Drug Development: Cost-Efficient Trial Design to Minimize Cash Burn


eTMF Workflows: Active eTMF to Improve the Quality of Clinical Trials


Copyright © 2016-2017 Honeycomb Worldwide Inc.